Fate Therapeutics Inc FATE

Healthcare Biotechnology

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

NDAQ:FATE - Post by User

Fate Therapeutics Inc > Article on Finpedia.co

<< Previous

Bullboard Posts

Next >>

Post by wiltonioon Jan 02, 2019 5:29pm

136 Views

Post# 29179137

Article on Finpedia.co

Finpedia is a stock market wiki that is assembling stock background reports for every publicy-traded company in the world. Here is the start of the FATE background report: https://finpedia.co/bin/Companies/Fate%20Therapeutics/

If you have an interest in helping, please jump in and help edit the doc.

<< Previous

Bullboard Posts

Next >>

Bombardier completes partial redemption of US$200 million